P406: AlphaE+ cells have increased expression of inflammatory markers and are correlated in the ileum and colonECCO '16 Amsterdam
2016
P407: Clinical manifestations of thiopurine S-methyltransferase variants in Korean paediatric patients with inflammatory bowel diseaseECCO '16 Amsterdam
2016
P408: Are pharmacokinetics more unfavourable in inflammatory bowel disease patients aged over 60 years?ECCO '16 Amsterdam
2016
P409: Impact of biological therapy in postoperative morbidity in elective surgical resections in Crohn’s diseaseECCO '16 Amsterdam
2016
P410: Segmental endoscopic scoring improves outcome prediction in acute severe colitisECCO '16 Amsterdam
2016
P411: Four-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patientsECCO '16 Amsterdam
2016
P412: Evolution of patients with ulcerative colitis who withdraw the maintenance treatment with mesalazineECCO '16 Amsterdam
2016
P413: Endoscopic balloon dilatation of Crohn’s strictures is safe and effective in selected casesECCO '16 Amsterdam
2016
P414: Usefulness of ultrasonography in the assessment of postoperative recurrence of Crohn’s diseaseECCO '16 Amsterdam
2016
P415: Therapeutic drug monitoring of thiopurines in the management of Asian patients with inflammatory bowel diseaseECCO '16 Amsterdam
2016
P416: An online educational portal is effective in improving knowledge regarding reproduction and IBDECCO '16 Amsterdam
2016
P418: Ulcerative colitis and end-stage liver disease in children with primary sclerosing cholangitisECCO '16 Amsterdam
2016
P419: Efficacy of vedolizumab in patients with inflammatory bowel disease and failure of anti-TNF-antibodiesECCO '16 Amsterdam
2016
P420: Does vedolizumab change mural vascularisation in ulcerative colitis and is there a correlation with endoscopic findings?ECCO '16 Amsterdam
2016
P421: Skin side effects of biologic therapy and systemic drugs in patients with inflammatory bowel diseasesECCO '16 Amsterdam
2016
P422: Risks and clinical features of active tuberculosis developed in patients with inflammatory bowel disease receiving anti-tumour necrosis factor therapyECCO '16 Amsterdam
2016